- BMSystems will participate to BIO in Boston, June 18-21; and Bio-Europe in Hamburg November, 12-14.
- Munich,may 11-12, 2012: BMSystems' CSO François Iris, is invited as session chairman to the 8th International Workshop on Computational Neuropsychiatry: Sleep, Affective disorders and Schizophrenia - An integrated view.
- Press-Release-Feb-2012: Pherecydes Pharma secures a €1.2-million Defense agency funding for evaluating the use of bacteriophages against infected, antibiotic resistant burns.
Downloads
BMSystems European Commission Conference Presentation
The EC "From Systems Biology to Systems Medicine" report
Industrial biotech World cluster
Spin-off sites
BMSystems history
1989 -1993 Dr. Iris is Group Leader at the CEPH in Paris
- The CEPH is a Research Institute founded and lead by Nobel laureate Prof. Jean Dausset.
- Develops methods for high-throughput (HT) sequencing & data integration.
- Realizes that the links between genome & biological processes are non-linear.
- One gene = several proteins = multiple interactions = many context-dependent functions.
1993 -1996 Dr. Iris creates & leads Millennium Pharmaceuticals' (USA) HT Sequencing Unit
- He undertakes the first attempts to carry-out physiological modeling via large scale data integration.
- He invents & develops the basic tools and methods required for Integrative Biology.
- Successful completion of two models, leading to the discovery of the UCP2 and EST1 genes and their roles in obesity and hyperglycemia.
- He realizes that since published information is:
- incomplete (to an unknown extent),
- slanted (to an unknown extent),and often
- incorrect (to an unknown extent).
- Methodologies to access/generate complementary unbiased information are required
1996-2001 - Dr. Iris is co-founder and C.S.O. of ValiGen SA in Paris
- He invents, develops and patents 4 new differential gene-expression and genotyping technologies.
- He invents and develops the computerized data gathering, data mining, clustering and integration tools & technologies necessary for the industrial development of Integrative Biology / Systems Biology (European "Eureka" grant: 18.6 M Euros).
- He finalizes the Bio-Graph™ analytical platform based on the "positive selection" concept.
- He develops the Tamoxifen Resistance model with Bio-Graph™.
- He identifies the limitations of this analytical platform.
1999-2001 - Dr. Iris meets Mr. M.Gea and Dr. G.Dine
- Dr. Iris meets M.Gea and Prof. G.Dine, founding members of Centrale-Santé.
- Dr. François Iris becomes a member of Centrale-Santé's Directorate, the Healthcare & Biotech Think Tank of the Centrale's alumni's Association.
- He decides to abandon the Bio-Graph™ platform and starts working on a second Generation analytical platform (CADI™) based on the negative selection concept.
- He starts to work on the first version of the Creutzfeldt-Jakob Disease model.
2002-2003 - Dr. Iris, M. Gea and Dr. Dine initiate the BMSystems project
- Conception of the first European private biotech company specialized in Predictive Integrative biology / Systems Biology.
- Paul-Henri Lampe, and Pablo Santamaria, members of Centrale-Santé Think Tank, decide to join the project.
- Development of the CADI™ analytical platform.
- Four new models completed (FGF4-driven fibroblast differentiation, hypercholesterolemia, Chronic Fatigue Syndrome, Creutzfeldt Jakob disease) two of which are undergoing independent biological evaluation.